MAP2K7 and neoplasm: Treatment of BRAF-mutated NECs with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib prevented tumor growth in a xenograft model [52] and also have been reported in single-case reports of patients with metastatic NECs to cause an objective tumor response [51].